David Kelly is a member of the Executive Committee of Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, and a Director of its Irish operating subsidiary. He was formerly the Executive Vice President, Managing Director, Ireland and Company Secretary of Horizon. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG.

Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

Mark Chin has over ten years of experience in the life sciences industry. He is currently a managing director at Arix Bioscience and a director of Harpoon Therapeutics, Imara, Pyxis Oncology and a number of privately held biotechnology companies. Prior to Arix, Mark was a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.

Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.

Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Mr. Hunt was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Mr. Hunt has played a significant role in many of the firm’s investments in biopharmaceuticals and in other sectors. Mr. Hunt is currently on the boards of Rallybio Holdings LLC and Harpoon Therapeutics Inc., and serves as director on the boards of a number of private companies. Mr. Hunt was previously on the boards of Neuronetics, Inc. (Nasdaq: STIM), Durata Therapeutics (Nasdaq: DRTX, acquired by Actavis), Relypsa (Nasdaq: RLYP), Cerexa (acquired by Forest Laboratories), Stromedix, Inc. (acquired by Biogen Idec), Aspreva Pharmaceuticals (Nasdaq: ASPV, acquired by Galenica, Inc.), Phase Forward (Nasdaq: PFWD, acquired by Oracle), and Pathology Partners (acquired by Caris Group).

Prior to joining Sprout in early 1998, Mr. Hunt was a consultant with the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Mr. Hunt held a number of sales and marketing positions for a combined eight years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals.

Mr. Hunt is a graduate of The Wharton School (MBA) and Cornell University (BS).

Mark Chin has over ten years of experience in the life sciences industry. He is currently a managing director at Arix Bioscience and a director of Harpoon Therapeutics, Imara, Pyxis Oncology and a number of privately held biotechnology companies. Prior to Arix, Mark was a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.

Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.

Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Mr. Hunt was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Mr. Hunt has played a significant role in many of the firm’s investments in biopharmaceuticals and in other sectors. Mr. Hunt is currently on the boards of Rallybio Holdings LLC and Harpoon Therapeutics Inc., and serves as director on the boards of a number of private companies. Mr. Hunt was previously on the boards of Neuronetics, Inc. (Nasdaq: STIM), Durata Therapeutics (Nasdaq: DRTX, acquired by Actavis), Relypsa (Nasdaq: RLYP), Cerexa (acquired by Forest Laboratories), Stromedix, Inc. (acquired by Biogen Idec), Aspreva Pharmaceuticals (Nasdaq: ASPV, acquired by Galenica, Inc.), Phase Forward (Nasdaq: PFWD, acquired by Oracle), and Pathology Partners (acquired by Caris Group).

Prior to joining Sprout in early 1998, Mr. Hunt was a consultant with the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Mr. Hunt held a number of sales and marketing positions for a combined eight years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals.

Mr. Hunt is a graduate of The Wharton School (MBA) and Cornell University (BS).

David Kelly is a member of the Executive Committee of Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, and a Director of its Irish operating subsidiary. He was formerly the Executive Vice President, Managing Director, Ireland and Company Secretary of Horizon. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG.

Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).